Last reviewed · How we verify
SARS-CoV-2 rS/Matrix M1-Adjuvant
SARS-CoV-2 rS/Matrix M1-Adjuvant is a vaccine that uses the SARS-CoV-2 spike protein and Matrix M1 adjuvant to stimulate an immune response against SARS-CoV-2.
SARS-CoV-2 rS/Matrix M1-Adjuvant is a vaccine that uses the SARS-CoV-2 spike protein and Matrix M1 adjuvant to stimulate an immune response against SARS-CoV-2. Used for Prevention of COVID-19.
At a glance
| Generic name | SARS-CoV-2 rS/Matrix M1-Adjuvant |
|---|---|
| Also known as | NVX-CoV2373 |
| Sponsor | Novavax |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by introducing the SARS-CoV-2 spike protein and Matrix M1 adjuvant to the body, which triggers an immune response and helps the body recognize and fight the virus. The Matrix M1 adjuvant enhances the immune response by activating immune cells and increasing the production of antibodies.
Approved indications
- Prevention of COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Safety and Immunogenicity of NVX-CoV2705 (PHASE3)
- Efficacy and Safety of NVX-CoV2705 (PHASE4)
- A Strain Change Study for SARS-CoV-2 rS Vaccines (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines (PHASE3)
- Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines (PHASE3)
- A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom (PHASE3)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 rS/Matrix M1-Adjuvant CI brief — competitive landscape report
- SARS-CoV-2 rS/Matrix M1-Adjuvant updates RSS · CI watch RSS
- Novavax portfolio CI